RCT: Nivolumab vs. placebo in patients with relapsed malignant mesothelioma.

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial – The Lancet Oncology

Commentary on Twitter

CONFIRM Trial: a phase III study demonstrated longer PFS and OS with Nivolumab compared with Placebo in patients with Pleural or Peritoneal Malignant Mesothelioma who have progressed following platinum-based chemotherapy @OncoAlert #LCSM https://t.co/jKoKXEXgpB

— Dipesh Uprety MD FACP (@DipeshUpretyMD) October 15, 2021